New hope for Tough-to-Treat pancreatic cancer?
NCT ID NCT03854110
Summary
This is an early-stage study to find a safe dose and check for side effects of a new drug called GP-2250 when given with an existing chemotherapy (gemcitabine). It is for adults with advanced pancreatic cancer that has worsened after a specific type of prior treatment. The main goal is to see how well patients tolerate the combination and gather initial clues about whether it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center at the University of Pennsylvania
Phildelphia, Pennsylvania, 19104, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Hoag Family Cancer Institute
Newport Beach, California, 92663, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27292, United States
Conditions
Explore the condition pages connected to this study.